Categories Earnings, Technology

Oracle’s (ORCL) Q3 results beat expectations

Oracle Corporation (NYSE: ORCL) topped revenue and earnings forecasts for the third quarter of 2020, allowing the stock to gain 3.7% in aftermarket hours on Thursday.  

Total revenues rose 2% year-over-year to $9.8 billion, surpassing estimates of $9.7 billion. Revenues were up 3% in constant currency.

Oracle beats Q3 2020 earnings and revenue estimates

GAAP net income fell 6% to $2.6 billion while GAAP EPS rose 4% to $0.79. Adjusted net income was $3.2 billion while adjusted EPS grew 11% to $0.97, beating forecasts of $0.96.

Short-term deferred revenues were $7.8 billion. Fusion ERP Cloud revenues were up 37% year-over-year on a reported basis and 38% in constant currency.

Subscription revenues were $6.9 billion, up 4% on a reported basis and 5% in constant currency. Subscription revenues now account for the majority of the company’s revenues. Cloud License and On-Premise License revenues were $1.2 billion, down 2% on a reported basis and flat on a constant currency basis. Hardware and Services revenues both saw decreases compared to the prior-year period.

Also read: Adobe Q1 2020 Earnings Report

For the fourth quarter, Oracle expects total subscription revenues to range between 3-5% in both constant currency and US dollars. Total revenues are expected to range between negative 2% to positive 2% in both constant currency and US dollars. Adjusted EPS is expected to grow 3-9% to a range of $1.20-1.28 in both constant currency and US dollars.

The Board of Directors declared a quarterly cash dividend of $0.24 per common share, payable to stockholders of record as of April 9, 2020, with a payment date of April 23, 2020. The company also increased its share repurchase authorization by $15 billion.

Oracle’s shares have fallen 24% over the past one year and 28% in the past one month.

Get access to timely and accurate verbatim transcripts that are published within hours of the event.

Most Popular

Earnings Preview: Johnson & Johnson bets on innovation to stay in growth mode

Over the years, Johnson & Johnson (NYSE: JNJ) has remained a dominant player in the medical industry, benefitting from its unique business model and growth strategy focused on constant innovation.

Key takeaways from PepsiCo’s Q3 2024 earnings report

Shares of PepsiCo, Inc. (NASDAQ: PEP) gained over 1% on Tuesday even though the company delivered mixed results for the third quarter of 2024 and lowered its guidance for the

PEP Earnings: All you need to know about PepsiCo’s Q3 2024 earnings results

PepsiCo, Inc. (NASDAQ: PEP) reported its third quarter 2024 earnings results today. Net revenue dipped 0.6% to $23.3 billion compared to the same period a year ago. Organic revenue growth

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top